Trajenta - Trajenta offers Simplicity for broad range of T2D patients

100 years of innovation for patients with cardiometabolic disease.

Trajenta® is manufactured in world-class facilities by or for Boehringer Ingelheim, one of the top 20 companies in the pharmaceutical industry.1

Quality Matters

Quality Matters It is ingrained in our approach to work, guiding us to consistently strive for excellence that we undertake.

Witness the Legacy of Trajenta

Trajenta is a medication used to treat type 2 diabetes by lowering blood sugar levels in adults.

Watch now

Quality Matters.

Boehringer Ingelheim takes the responsibility of manufacturing consistently reliable products...

Legacy Matters.

Boehringer Ingelheim has been dedicated to improving the lives of patients...

Experience Matters.

Since 2011#, physicians worldwide have valued their experience with Trajenta® across a broad...

the most appropriate therapeutic for T2D patients

Simple. Effective. Every day.^2-3

When a DPP4i is needed for T2D management, it may be difficult to select the most appropriate therapeutic for your patient.⁴ With Trajenta®, it's simple every day, thanks to proven efficacy, a demonstrated long-term CV and kidney safety profile, and the convenience of always one dose, once daily.^2-3That is why physicians worldwide have valued their experience with Trajenta® across a broad range of T2D patients, for nearly 10 years. Altogether, this confidence has driven more than 20 million patient-years of exposure to Trajenta®.⁵

Key Information

Indication³

Trajenta® is a prescription medicine used as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

Active Ingredient³

The active ingredient in Trajenta® is linagliptin, which is a dipeptidyl peptidase-4 inhibitor (DPP4i).

Dosage & Administration³

Trajenta® is available as an oral tablet in a single, 5mg dose.

Contraindications³

Trajenta® is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity.

Expand your knowledge

Resource Center

Videos. Infographics. Publications. We have an assortment of resources that you may find valuable in learning more about Trajenta® and how its Simplicity can help you in your daily management of type 2 diabetes patients.

Expand your knowledge

Footnotes

CV:
cardiovascular; CVOT: cardiovascular outcome trial; DPP4i: dipeptidyl peptidase-4 inhibitor; T2D: type 2 diabetes
*
Pooled analysis of data from 2,258 subjects in three 24-week phase III, randomised, placebo-controlled, parallel-group studies, who received oral linagliptin (5 mg/day) or placebo as monotherapy, added-on to metformin, or added-on to metformin plus sulphonylurea was performed. Adjusted mean HbA1c change from baseline with linagliptin was -1.2% (vs -0.4% with placebo, p<0.0001).³
†
Indicated for use in adult patients. Trajenta® is contraindicated in those with hypersensitivity to any of the active substances or excipients, is not licensed for paediatric use and should not be used in pregnant women.

References

1.
Boehringer Ingelheim, www.boehringer-ingelheim.com/corporate-profile/our-company.
2.
Del Prato S, et al. J Diab Compl. 2013;27:274–9.
3.
Trajenta® PI. Boehringer Ingelheim india Pvt. Ltd. Ver. 02 Aug. 2021.
4.
Davies M, et al. Diabetologia. 2018;61:2461-98.
5.
Boehringer Ingelheim, Data on File, 2021.

Trajenta®